Carisma Therapeutics, Inc. (CARM) Financial Analysis & Valuation | Quarter Chart
Carisma Therapeutics, Inc. (CARM)
CARMPrice: $0.01
Fair Value: 🔒
🔒score
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeri... more
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) m... more
Description
Shares
| Market Cap | $230,148 | Exchange | OTC |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Craig R. Jalbert |
| IPO Date | 2014-02-06 | CAGR | — |
| Employees | 46 | Website | carismatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CARM chart loading...
Fundamentals
Technicals
| Enterprise Value | $9.66M | P/E Ratio | 0.02 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $0.31 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 159.68% | Gross Margin | 0.98% |
| Operating Margin | 0.21% | Profit Margin | 0.15% |
| ROE | -0.29% | ROA | 1.23% |
| ROCE | -42.04% | Current Ratio | 0.86 |
| Quick Ratio | 0.86 | Cash Ratio | 0.41 |
| Debt/Equity | -0.88 | Interest Coverage | — |
| Altman Z Score | -45.89 | Piotroski Score | 3 |